Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Biotech Industry Analysis

UpdatedMay 09, 2026
DataAggregated Company Financials
Companies22
  • 7D0.02%
  • 3M-20.2%
  • 1Y14.8%
  • YTD-7.1%

Last week, the Biotech industry hasn't moved much but Oxford Biomedica is up 9.4% in that time. The past year has been better, since the industry has gained 15% in that time. Looking forward, earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the U.K. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 10 May 2026UK£3.1bUK£888.4m-UK£111,894,338.9019.3x-27.5x3.5x
Tue, 07 Apr 2026UK£3.1bUK£893.2mUK£3.1m9.2x991.1x3.5x
Thu, 05 Mar 2026UK£3.3bUK£875.5m-UK£4,343,657.429.2x-769.8x3.8x
Sat, 31 Jan 2026UK£3.9bUK£876.0m-UK£29,051,336.2410.7x-133.8x4.4x
Mon, 29 Dec 2025UK£3.2bUK£896.6m-UK£29,559,137.5010.3x-107.9x3.6x
Wed, 26 Nov 2025UK£3.1bUK£895.5m-UK£30,598,986.5910.9x-102.3x3.5x
Fri, 24 Oct 2025UK£3.2bUK£878.9m-UK£44,291,542.7515.5x-72.8x3.7x
Sun, 21 Sep 2025UK£3.4bUK£857.6m-UK£83,268,050.8716.2x-40.5x3.9x
Tue, 19 Aug 2025UK£3.3bUK£854.5m-UK£103,344,301.6211.8x-31.7x3.8x
Thu, 17 Jul 2025UK£2.9bUK£854.7m-UK£103,116,156.7413.2x-27.7x3.3x
Sat, 14 Jun 2025UK£2.6bUK£857.1m-UK£104,134,043.0013.4x-24.7x3x
Mon, 12 May 2025UK£2.4bUK£879.5m-UK£95,247,877.4113.2x-25.6x2.8x
Wed, 09 Apr 2025UK£2.1bUK£846.0m-UK£278,164,407.5416.9x-7.6x2.5x
Fri, 07 Mar 2025UK£2.4bUK£843.8m-UK£278,233,935.9317.7x-8.6x2.8x
Sun, 02 Feb 2025UK£2.8bUK£842.2m-UK£295,621,545.3390.8x-9.5x3.3x
Tue, 31 Dec 2024UK£2.6bUK£841.9m-UK£294,754,422.1673.8x-8.7x3x
Thu, 28 Nov 2024UK£2.7bUK£840.9m-UK£294,209,571.4582.8x-9.2x3.2x
Sat, 26 Oct 2024UK£3.0bUK£840.2m-UK£291,904,347.8596.8x-10.2x3.5x
Mon, 23 Sep 2024UK£2.8bUK£831.9m-UK£310,148,019.9088.2x-8.9x3.3x
Wed, 21 Aug 2024UK£2.6bUK£836.8m-UK£250,916,418.6430x-10.4x3.1x
Fri, 19 Jul 2024UK£2.6bUK£837.8m-UK£256,851,141.0429.2x-10x3.1x
Sun, 16 Jun 2024UK£2.6bUK£835.7m-UK£273,377,481.5729.4x-9.6x3.1x
Tue, 14 May 2024UK£3.0bUK£835.9m-UK£289,714,063.9231.5x-10.2x3.5x
Thu, 11 Apr 2024UK£3.1bUK£902.6m-UK£201,276,403.5529.3x-15.4x3.4x
Sat, 09 Mar 2024UK£3.1bUK£897.4m-UK£203,115,454.3534.5x-15.4x3.5x
Mon, 05 Feb 2024UK£6.4bUK£1.3b-UK£245,773,262.0037.4x-25.9x5x
Wed, 03 Jan 2024UK£6.4bUK£1.3b-UK£245,596,681.0037.9x-25.9x5x
Fri, 01 Dec 2023UK£6.1bUK£1.3b-UK£245,729,150.0035.9x-25x4.8x
Sun, 29 Oct 2023UK£6.4bUK£1.3b-UK£253,173,371.0036.9x-25.1x5x
Tue, 26 Sep 2023UK£6.5bUK£1.3b-UK£223,454,243.0023.9x-29.3x5.2x
Thu, 24 Aug 2023UK£6.6bUK£1.3b-UK£207,970,584.0023.6x-31.8x5.3x
Sat, 22 Jul 2023UK£6.9bUK£1.3b-UK£208,450,371.0023.9x-33.3x5.5x
Mon, 19 Jun 2023UK£7.0bUK£1.3b-UK£204,901,171.0023.1x-34.1x5.6x
Wed, 17 May 2023UK£6.9bUK£1.3b-UK£206,631,778.0023.1x-33.6x5.5x
Price to Earnings Ratio

-33.6x


Total Market Cap: UK£6.9bTotal Earnings: -UK£206,631,778.00Total Revenue: UK£1.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Biotech Industry Price to Earnings3Y Average -28.4x202420252026
Current Industry PE
  • Investors are relatively neutral on the British Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 3.8x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 11% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?

GB Market-0.81%
Healthcare-1.92%
Biotech0.021%
Biotech0.021%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
OXB Oxford BiomedicaUK£6.499.4%
+UK£67.7m		118.9%PS4.7x
AVCT Avacta GroupUK£0.8210.0%
+UK£34.0m		151.9%PS3309.3x
SCLP Scancell HoldingsUK£0.1712.6%
+UK£19.7m		70.0%PS37.4x
CIZ Cizzle Biotechnology HoldingsUK£0.03117.0%
+UK£1.8m		106.7%PE-17.8x
FARN Faron Pharmaceuticals OyUK£0.421.2%
+UK£997.6k		-81.7%PE-3.6x

Latest News

AVCT
UK£0.82
Avacta Group
7D
10.0%
1Y
151.9%
4BB
UK£4.55
4basebio
7D
-9.9%
1Y
-59.6%
SVNS
UK£0.0024
Solvonis Therapeutics
7D
-4.0%
1Y
45.5%
GNS
UK£23.20
Genus
7D
-1.5%
1Y
10.0%
Narrative Update • May 03

GNS: China Joint Venture Cash Inflow Will Drive Medium Term Upside

Analysts have kept the Genus fair value target steady at £37.00, while modestly adjusting underlying assumptions on discount rate, profit margin and future P/E to reflect a mix of bullish and neutral initiation views in recent research. Analyst Commentary Recent initiation coverage signals a mixed but generally constructive tone on Genus, with one major bank expressing clear optimism and others adopting a more neutral stance.
OXB
UK£6.49
Oxford Biomedica
7D
9.4%
1Y
118.9%
Narrative Update • May 03

OXB: Future Cash Generation And Execution Risks Will Shape Balanced Outlook

Analysts have lifted their price target on Oxford Biomedica to £5.50, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that support a more refined view of the stock’s risk and earnings profile. Analyst Commentary Recent research coverage frames Oxford Biomedica as an opportunity with a refreshed risk and earnings profile, but not all commentary is uniformly positive.
PRTC
UK£1.27
PureTech Health
7D
-8.4%
1Y
1.6%
SCLP
UK£0.17
Scancell Holdings
7D
12.6%
1Y
70.0%
HEMO
UK£6.90
Hemogenyx Pharmaceuticals
7D
1.9%
1Y
279.9%
GENF
UK£0.024
Genflow Biosciences
7D
-11.1%
1Y
166.7%
CIZ
UK£0.031
Cizzle Biotechnology Holdings
7D
17.0%
1Y
106.7%
FARN
UK£0.42
Faron Pharmaceuticals Oy
7D
1.2%
1Y
-81.7%
BVXP
UK£17.00
Bioventix
7D
-1.4%
1Y
-40.4%
APTA
UK£0.006
Aptamer Group
7D
-4.0%
1Y
62.2%
0KF3
US$18.50
Palatin Technologies
7D
-15.5%
1Y
297.8%